TLSATiziana Life Sciences Ltd

Nasdaq tizianalifesciences.com


$ 1.23 $ 0.01 (0.81 %)    

Tuesday, 27-Aug-2024 15:59:37 EDT
QQQ $ 476.56 $ 1.42 (0.3 %)
DIA $ 412.95 $ 0.17 (0.04 %)
SPY $ 561.57 $ 0.77 (0.14 %)
TLT $ 97.97 $ -0.17 (-0.17 %)
GLD $ 233.38 $ 0.63 (0.27 %)
$ 1.24
$ 1.23
$ 1.23 x 100
-- x --
$ 1.23 - $ 1.24
$ 0.41 - $ 1.74
54,060
na
127.83M
$ 0.75
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 tiziana-life-sciences-appoints-ivor-elrifi-as-its-ceo-effective-immediately

Elrifi succeeds Gabriele Cerrone, who was acting CEO and will remain in his role as Executive Chairman of the board and will co...

Core News & Articles

TSLANVDAWAYAITLRYQQQAAPLAVGOSMCIAMZNData from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment 

 tiziana-life-sciences-reports-six-month-qualitative-results-for-all-10-non-active-secondary-progressive-multiple-sclerosis-patients-enrolled-in-intermediate-size-patient-population-expanded-access-program

Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded A...

 tiziana-life-sciences-reports-3-month-neuroimaging-scores-in-multiple-sclerosis-patients-receiving-intranasal-foralumab-a-primary-endpoint-with-clinical-measures-of-edss-disability-and-mfis-fatigue-is-currently-underway

Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing brea...

 tiziana-life-sciences-announces-fda-allowance-for-additional-patients-to-be-enrolled-in-intranasal-foralumab-multiple-sclerosis-expanded-access-program

Program to expand from 10 patients to a total of 30 patients.

 tiziana-life-sciences-announces-additional-clinical-improvements-among-multiple-sclerosis-patients-in-its-expanded-access-program

Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing brea...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION